AVROBIO, a biotechnology company developing single-dose gene therapies for rare diseases, announced positive preliminary data for its Phase 1/2 clinical trial testing AVR-RD-01 gene therapy in patients with Fabry disease. AVR-RD-01 has shown to be safe and effective in delivering a healthy GLA gene that encodes a functional…
News
A study in a Nordic population found no apparent clinical benefit in screening patients with idiopathic small fiber neuropathy or mixed neuropathy for hereditary ATTR amyloidosis and Fabry disease, identifying no definite cases of either disorder. The study, “Screening for Fabry disease and hereditary ATTR amyloidosis in idiopathic…
A case study detailing a younger man admitted to a hospital for a stroke — later attributed to Fabry disease — highlights the importance of family history in diagnosing diseases, especially rare diseases like Fabry, that have a wide range of clinical manifestations. The case report, “Fabry Disease Diagnosis…
More than 700 medical experts, pharmaceutical executives, patient advocates, and others are expected to converge on Washington, D.C., next month for the 2018 NORD Rare Diseases & Orphan Products Breakthrough Summit. The Oct. 15-16 event, sponsored by the National Organization for Rare Diseases (NORD), takes place at the…
The intracranial volume (ICV) in patients with Fabry disease is significantly lower than in healthy individuals, indicating an early onset of neurodevelopmental abnormality, according to researchers. Their study, “Reduced Intracranial Volume in Fabry Disease: Evidence of Abnormal Neurodevelopment?” was published in the journal Frontiers in Neurology. Fabry…
Protalix BioTherapeutics‘ investigational therapy PRX-102 (pegunigalsidase alfa) improved kidney function in Fabry disease patients, according to preliminary Phase 3 clinical results. The company announced that additional positive preliminary data of its BRIDGE clinical trial will be presented during the Canadian Symposium on Lysosomal Diseases, taking place Oct. 5-6 in Sherbrooke,…
Roughly half of the patients diagnosed with Fabry disease experience white matter lesions, which tend to develop earlier in males and are more prevalent as patients get older, a review study shows. The study, “Development and clinical consequences of white matter lesions in Fabry disease: a systematic review,”…
Fabry disease patients struggle with physical exercise — measured by a cardiopulmonary exercise test — due to an impairment in cardiac function as a direct consequence of Fabry-associated heart disease, a study shows. The study, “Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease,”…
Renal insufficiency in Fabry disease patients may lead to cellular events that result in cardiovascular disease, a study shows. The study, “Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy,” was published in the journal Frontiers in Cardiovascular Medicine. Fabry disease patients are unable to produce an…
Inflammation of the heart, known as myocarditis, is found in more than half of patients with Fabry disease cardiomyopathy — a consequence of fat molecule accumulation in the cells of the heart — and is associated with disease severity, a study has found. Myocarditis may also limit the impact…
Recent Posts
- US developer gets rights to potential Fabry drug in deal worth up to $475M
- Film explores how to find joy amid suffering and hope within despair
- Phase 3 trial launches to evaluate new treatment for Fabry disease
- Long-term therapy stabilizes eye health in Fabry disease, study finds
- Staying active can be challenging with Fabry disease and chronic pain